Integrating Artificial Intelligence Into Lung Cancer Screening.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

2722 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-08

Study Completion Date

2030-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lung cancer (LC) screening using low-dose chest CT (LDCT) has already proven its efficacy.

The mortality reduction associated with LC screening is around 20%, much higher than the reduction in mortality associated with screening for breast, colon or prostate cancers.

Implementing lung cancer screening on a large scale faces two main obstacles:

1. The lack of thoracic radiologists and LDCT necessary for the eligible population (between 1.6 and 2.2 million people in France);
2. The high frequency of false positive screenings: in the NLST trial, more than 20% of the subjects screened were found to have at least one nodule of an indeterminate lung nodule (ILN) whereas less than 3% of ILNs are actually LC.

The gold standard for determining on the benign or malignant nature of a nodule is definitive histology. Otherwise, the evolution of the nodule on serial thoracic imaging is a good alternative. The period of indeterminacy of a nodule can be as long as 24 months in many cases, which can be a source of prolonged and sometimes unjustified anxiety for screening candidates.

The purpose of this randomized controlled study that focuses on LC screening in patients aged 50 to 80 years, who smoked more than 20 packs/ year or stopped smoking less than 15 years ago. Its objective is to determine whether assisting multidisciplinary team (MDT) meetings with an AI-based analysis of screening LDCT accelerates the definitive classification of nodules into malignant or benign.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Evaluation of the Lung Cancer AI-based Decision Support Tool in Low-Dose Lung CT

NCT07052773

Lung Cancer Screening

COMPLETED

Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT

NCT06910956

Lung Cancer Health Screening Early Cancer Detection +1 more

RECRUITING NA

AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs

NCT06320184

Lung Cancer Blood Biomarkers

ACTIVE_NOT_RECRUITING

Artificial Intelligence in Lung Cancer Screening

NCT06444373

Lung Cancer Screening Asbestos

COMPLETED

Lung Nodule Imaging Biobank for Radiomics and AI Research

NCT04270799

Lung Cancer Pulmonary Nodule, Multiple Pulmonary Nodule, Solitary +1 more

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IA Group

Patients with at least one nodule (\> 6mm) for whom the multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography

Group Type EXPERIMENTAL

IA

Intervention Type OTHER

The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography

Group not IA analysis

Patients with at least one nodule (\> 6mm) for whom the multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography

Group Type OTHER

Not IA

Intervention Type OTHER

The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IA

The multidisciplinary team meeting discussion is informed of the AI-based analysis of their chest computed tomography

Intervention Type OTHER

Not IA

The multidisciplinary team meeting discussion is not informed of the AI-based analysis of their chest computed tomography

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 50 and 80 years old
* active smoker or ex-smoker who quit smoking less than 15 years ago
* smoking history of at least 20 pack-years
* signature of the informed consent
* affiliation to French social security

Exclusion Criteria

* clinical signs suggestive of cancer
* recent chest scan (\<1 year) for another cause
* radiological abnormality requiring follow-up or additional investigations
* health problem significantly limiting life expectancy from the clinician's point of view
* health problem limiting ability or willingness to undergo lung surgery
* Patients with active neoplasia, except basal cell carcinoma of the skin.
* vulnerable people: adults under guardianship, adults under curatorship medical and/or psychiatric problems of sufficient severity to limit full adherence to the study or expose patients to excessive risk

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No